annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
3:00 PM - 5:30 PM
ORAL ABSTRACT SESSION
Lung Cancer—Metastatic
Location: E Hall D2
CME credit: 2.5
Track(s): Lung Cancer
Nithya Ramnath, MD—Co-Chair
University of Michigan
Lecia Sequist, MD—Co-Chair
Massachusetts General Hospital
3:00 PM Randomized phase II trial of erlotinib (E) alone or in combination with
carboplatin/paclitaxel (CP) in never or light former smokers with advanced
lung adenocarcinoma: CALGB 30406. (Abstract #7503)
P. A. Janne, X. F. Wang, M. A. Socinski, J. Crawford, M. Capelletti, M. J. Edelman,
M. A. Villalona-Calero, R. A. Kratzke, E. E. Vokes, V. A. Miller
3:15 PM TOPICAL: Randomized phase III trial of erlotinib compared with placebo in
chemotherapy-naive patients with advanced non-small cell lung cancer
(NSCLC) and unsuitable for first-line chemotherapy. (Abstract #7504)
S. Lee, R. Rudd, I. Khan, S. Upadhyay, C. R. Lewanski, S. Falk, G. Skailes,
R. Partridge, Y. Ngai, C. Boshoff
Discussion
3:30 PM Fadlo Raja Khuri, MD (Abstracts #7503–7505)
Winship Cancer Institute at Emory University
EGFR Inhibitors: Are We Done Yet?
3:45 PM Phase III study of maintenance gemcitabine (G) and best supportive care
(BSC) versus BSC, following standard combination therapy with
gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell
lung cancer (NSCLC). (Abstract #7506)
C. P. Belani, D. M. Waterhouse, H. Ghazal, S. S. Ramalingam, R. Bordoni,
R. Greenberg, R. M. Levine, J. M. Waples, Y. Jiang, G. Reznikoff
4:00 PM Maintenance with either gemcitabine or erlotinib versus observation with
predefined second-line treatment after cisplatin-gemcitabine induction
chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.
(Abstract #7507)
M. Perol, C. Chouaid, B. J. Milleron, R. Gervais, F. Barlesi, V. Westeel, J. Crequit,
H. Lena, A. Vergnenegre, D. Pérol
4:15 PM International multicenter randomized phase III study of first-line erlotinib (E)
followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG
followed by second-line E in advanced non-small cell lung cancer (aNSCLC):
The TORCH trial. (Abstract #7508)
C. Gridelli, F. Ciardiello, R. Feld, C. A. Butts, V. Gebbia, G. Genestreti,
A. G. Favaretto, R. Wierzbicki, C. Gallo, F. Perrone, on behalf of the TORCH
Investigators
Discussion
4:30 PM Gregory Peter Kalemkerian, MD (Abstracts #7506–7508)
University of Michigan
Maintenance Therapy: Are We There Yet?
4:45 PM Effect of early palliative care (PC) on quality of life (QOL), aggressive care at
the end-of-life (EOL), and survival in stage IV NSCLC patients: Results of a
phase III randomized trial. (Abstract #7509)
J. S. Temel, J. Greer, E. Gallagher, S. Admane, W. F. Pirl, V. Jackson, C. Dahlin,
A. Muzikansky, J. Jacobsen, T. J. Lynch
406